This retrospective study investigated the impact of Oncotype DX (ODX) on the newly updated breast cancer staging system. Of the 816 cases reviewed, ODX rarely affected stage, thus supporting the American Joint Committee on Cancer 8th edition expert panel's statement that ODX is not required for staging. Purpose: The 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system requires histologic grade (GR), estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and stage (assessed by the tumor, node, metastasis classification system). For T1-2 N0, ER Sixty-one percent of cases of recurrence (11/18) were downstaged using the new staging system. Conclusion: ODXRS has little influence on staging, thus supporting the view of the AJCC 8th edition expert panel that ODX is not required for staging. Downstaging of more than half of cases of recurrence suggests that continued refinement of the staging system, as proposed by the expert panel, could be beneficial in this subgroup of patients.
Introduction
The 8th edition of the American Joint Committee on Cancer (AJCC) breast cancer staging system, published in October 2016 and updated in November 2017, established a new staging system that combines histologic grade (GR) and biological markers with traditional anatomic stage (tumor, node, metastasis classification system, TNM), resulting in better discrimination among stage group assignment than TNM alone. 1 Anatomic stage is now used only in areas of the world where biologic markers are not available. The prognostic stage was devised using survival data from the National Cancer Data Base for women diagnosed with invasive mammary carcinoma (IMC) from 2010 to 2012. 1, 2 Using different growth factor receptor 2 (HER2) resulted in 120 categories of patients. Survival was determined for each category, and a prognostic stage group (PSG) was assigned. Triple negative and GR3 IMC showed decreased survival, while ER þ /PR þ IMC, regardless of HER2 status, showed better survival compared to tumors in the same 7th edition stage group. These results were consistent with published data by Mittendorf et al 3 utilizing Bioscore, a proposed staging system combining TNM, GR, ER, and HER2 that was subsequently validated using Surveillance, Epidemiology, and End Results data and the California Cancer Registry. 4 The new staging system consists of a clinical prognostic stage and a pathologic prognostic stage (PPS), with the latter used for patients who receive surgical resection as the initial treatment and the former for all other patients. The expert panel notes that the new staging system is only relevant in the context of appropriate therapy. 1 In addition to GR and receptor status, the PPS table includes an Oncotype DX (ODX) recurrence score (RS) of < 11. ODX is a 21-gene reverse transcriptase PCR assay that predicts chemotherapy benefit in patients with ER þ /HER2À, lymph node (LN)-negative IMC. Although ODX is available for 1 to 3 LN-positive IMC, the American Society of Clinical Oncology (ASCO) recommendations for testing are restricted to IMC node-negative, isolated tumor cell, or micrometastatic nodal disease. 5, 6 In the TAILORx trial, a subgroup of patients with T1-2 N0, hormone receptor positive, and HER2À IMC who had an ODXRS < 11 (arm A of the trial) were treated systemically with adjuvant endocrine therapy alone and were found to have a 5-year distant recurrence-free survival of 99.3%. 7 On the basis of these findings (recognized as AJCC level I evidence), breast cancer (BC) can be staged as pathologic PSG (pPSG) IA 1 if the patient meets the eligibility criteria for arm A of the TAILORx study. ODX is one of many multigene panels. However, as of the November 2017 version of the AJCC 8th edition, ODX is the only multigene panel included to assign pPSG, as stated in note 3 of the pPSG table. 1 Although the 8th edition's expert panel emphasizes that use of ODX is not required for staging and that they do not endorse its use over other panels for treatment purposes, 1 it remains to be determined if the PPS will influence any changes in practice when ordering these tests. The National Comprehensive Cancer Network guidelines recommend ODX for hormone receptor positive HER2À IMC, > pT1a and pN0, pN0(iþ) or pN1mi. 8 However, this assay is not necessarily ordered on all IMC that meet the criteria. Many studies have demonstrated that routine pathologic parameters can predict ODXRS without the high cost or delays in treatment while awaiting ODX results. Most notable is the IHC4 score, which is a prognostic algorithm based on immunohistochemistry (IHC) results of ER, PR, HER2, and Ki-67, and which has been shown to have similar prognostic value as the ODXRS. 9 Because the PPS incorporates many of these same routine histologic parameters, the ODXRS may have a limited impact on staging. To achieve a better understanding of how ODXRS influences staging, we reviewed cases of IMC that were ER þ /HER2À with available ODX results and determined the proportion of cases that would be downstaged as a direct result of the ODXRS using the PPS. We also sought to identify routine pathologic parameters that could predict whether the ODXRS would change the stage.
Materials and Methods
This was a retrospective study with institutional review board approval. was not provided in all cases, and therefore ER/PR percentage staining was used for analysis. An ER/PR cutoff of 33% was used to distinguish low ( 33% staining) versus high (> 33% staining) ER/PR status and is based on the Allred proportion scores of 0 through 3 (0%-33% staining) and scores of 4 and 5 (> 33% staining), respectively, for percentage staining of tumor nuclei. 12 Mattes et al 13 showed routine histopathologic characteristics can predict ODXRS; they used the Allred score, the sum of the proportion score plus intensity score, for ER/PR analysis. Mattes et al used an Allred score cutoff of 4, where scores of 0 to 4 indicated negative/weak staining and scores of 5 to 8 strong staining. For an Allred score of 4, the proportion score can be no greater than a score of 3 (nuclear staining 10%-33%). A Ki-67 cutoff of 20% was used and is based on the cutoff value favored by the St Gallen 2013 expert panel. 14 A low Ki-67 refers to < 20% staining, and a high Ki-67 refers to ! 20% staining. The anatomic stage group (ASG) and pPSG were determined for each case using the most recent version of the AJCC 8th edition staging system. 1 The number of cases with a change in stage when comparing ASG to pPSG was calculated. To determine the effect that ODXRS has on staging, pPSG without ODXRS and pPSG with ODXRS were recorded for each case, and the number of cases with a change in stage was calculated. Per the 8th edition, assignment of pPSG IA with ODXRS < 11 only applies to a subgroup of tumors that are T1-2, N0, M0, ER þ /HER2À. Therefore, T1-2 N0
cases were analyzed separately. Associations between continuous factors with ODX risk were tested by t test or ANOVA, and associations between categorical factors with ODX risk were tested by the chi-square or Fisher exact test for the expected frequency, within any cell < 5 in a 2 Â 2 table. 15, 16 The descriptive statistics of tumor characteristics for 816 patients are summarized in Table 1 . Table 2 shows treatment by subgroup.
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The results from comparing ODX risk among factor groups for 663 patients with T1-2N0 cases using TAILORx categories are presented in Table 3 . Associations were considered significant at P < .05. All calculations were performed by SAS 9 statistical software (SAS Institute, Cary, NC).
Results
A total of 816 ER
þ /HER2À cases were identified that met our criteria. Clinicopathologic characteristics are summarized in Table 1 . When comparing ASG to pPSG, 351 (43%) of 816 cases changed stage using pPSG (Table 1 ). Of the cases that changed stage, all (100%) were downstaged, with 74% (258/351) downstaged to pPSG IA. Only 4 (0.5%) of the 816 cases changed stage as a direct result of the ODXRS, and all were T2N0 that were either GR3 and strongly ER þ and PR þ or GR2 and PRÀ (Table 4) . Of note, all 4 cases had high Ki-67. All ODX risk categories and subcategories using standard and TAILORx cutoffs were significantly associated with GR, PR, and Ki-67 ( Figure 1A -C). These associations maintained significance when analyzing only T1-2N0 tumors (Table 3) . Although a Ki-67 cutoff of 20% was significantly associated with all ODX risk categories, a high Ki-67 was seen in 20% (31/153) of all vLR cases ( Figure 1B ) and 22% (25/116) of T1-2 N0 vLR cases (Table 3) .
Analysis of all 166 vLR cases showed that 95% (158 cases) were either GR1 or GR2 ( Figure 1A ). Of the 166 cases, 81 (49%) were T1N0, 19 (11%) were T1N1, 47 (28%) were T2N0, 14 (8%) were T2N1, 4 (3%) were T3N0, and 1 (1%) was T3N1. When using PPS, 158 (95%) were group IA and 8 (5%) were IB. Percentage ER and PR were available in 165 (99%) of the 166 vLR cases. Two cases (1%) were low ER, and 15 (9%) were low PR, with 4 cases (2%) that were PRÀ ( Figure 1C ). All low ER and low PR cases were GR1 or GR2. All 4 PRÀ cases had high ER, with 2 (50%) that were GR1 with low Ki-67, and 2 (50%) that were GR2 with high Ki-67. One PRÀ case was T2N0 and was downstaged from pPSG IIA to IA on the basis of ODXRS (Table 4 , case 1). Two PRÀ cases were T1N0 and thus were already pPSG IA, and one was T1N1a not meeting criteria for downstaging with ODXRS. Ki-67 was available in 153 (92%) of the 166 vLR cases (median, 10%; range, 0%-40%), and 80% (122/153) had low Ki-67 ( Figure 1B ). Eight (5%) of 166 vLR cases were GR3, and all (100%) were high ER and PR ( Figure 1D ), with percentage staining ranging from 84% to 100%. For these 8 cases, Ki-67 ranged from 15% to 30% (median, 20%; mean, 22%). Three (38%) of the 8 GR3 cases were T2N0 and were downstaged from pPSG IB to IA 
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In contrast, analysis of all HR cases showed that 76% were GR3 (52/68) ( Figure 1A ). Of these 68 HR cases, 40 (59%) were T1N0, 20 (29%) were T2N0, 6 (9%) were T2N1, 1 (1%) was T3N0, and 1 (1%) was T3N1. Forty-three HR cases (63%) were pPSG IA, 10 (15%) were IB, 10 (15%) were IIA, and 5 (7%) were IIB. Twelve HR cases (18%) were low ER, and all were associated with low PR. Fifty-three HR cases (78%) were low PR, and of these, 18 (34%) were PRÀ ( Figure 1C ). Thirteen PRÀ cases (72%) were GR3. Ki-67 was available in 63 (93%) of the 68 HR cases and ranged from 5% to 90% (median, 40%; mean, 38%), with 13 low Ki-67 cases (19%) ( Figure 1B ). Of the 52 GR3 tumors in the HR category, only 12 (23%) had high ER and PR ( Figure 1D ). Ki-67 results were available in 10 (83%) of these 12 cases, with indices ranging from 5% to 90% (median, 35%; mean, 42%). Of note, the 2 cases that were GR1 in the HR category were both invasive lobular carcinoma and pN0. One was a 0.8 cm tumor with 80% ER, 0% PR, and 5% Ki-67; the second was a 3.4 cm tumor with 20% ER, 5% PR, and 7.5% Ki-67.
Follow-up was available in 409 (50%) of 816 cases and ranged from 2 to 129 months (median, 60 months; mean, 56.28 months). Data regarding adjuvant systemic therapy were available in 376 (92%) of 409 cases (Table 2) , and 303 of the 376 cases (81%) were T1-2N0 (Table 3) . Cases with follow-up included 70 (42%) of 166 vLR cases, 162 (55%) of 295 rLR cases, 121 (54%) of 223 LIR cases, 29 (45%) of 64 HIR cases, and 27 (40%) of 68 HR cases. Eighteen (4%) of 409 patients with follow-up experienced recurrence (Table 5) . Sixty-one percent of patients (11/18) who experienced recurrence were downstaged on the basis of the new staging system, with 44% (8/18) downstaged from either stage II or III to stage I. None of the cases were downstaged on the basis of ODXRS. Of these 18 cases, 1 (6%) was in the vLR category, 11 (61%) were rLR/LIR, and 6 (33%) were HIR/HR. The single patient in the vLR group had disease staged as IA by ASG and pPSG (Table 5, 
Discussion
The most significant change introduced in the 8th edition of the AJCC breast cancer staging system is the prognostic stage. In our review of ER þ /HER2À IMC, the disease of close to half of our patients changed stage using required biologic markers alone, and all were downstaged with the majority to IA. Only rare cases were downstaged on the basis of the ODXRS. This is the result of several factors. First, the ability of ODXRS to change stage is limited to tumors that meet the criteria for arm A of the TAILORx trial. 7 Our findings show that the majority of these tumors are both ER þ and PR þ and GR1 or GR2. Sparano et al 7 had similar findings for this subgroup, with > 99% ER þ , 98% PR þ , and 93% GR1 or GR2.
Thus, the required biologic markers that downstage ER þ /HER2À tumors to pPSG IA overlap with the biologic characteristics of tumors that tend to have an ODXRS < 11. Second, the number of cases eligible for downstaging on the basis of ODXRS is further limited to T2N0 tumors that are either PRÀ or GR3, because all other tumors fitting the criteria for arm A of TAILORx are already pPSG IA. Sparano et al reported that 31% (505/1626) of tumors measured 2.0 to 5.0 cm, 7% (111/1578) were GR3, and 2% (28/ 1590) were PRÀ in arm A. Our study shows similar findings (Table 3) , with only 10% (67/663) of T1-2N0 cases that were T2N0 and either GR3 or PRÀ. Therefore, the probability is low that ODXRS will change stage based on the current PPS table.
Although the 8th edition does not require an ODXRS result for pPSG, our analysis identified pathologic parameters that are associated with potential for downstaging based on an ODXRS < 11. These parameters include classification as T2N0 and tumors that are either GR3 with high ER and high PR, or GR1-2 and ER þ / PRÀ ( Figure 2 ). In contrast, GR3 tumors that are either low ER or low PR, or both ER and PR low predict an ODXRS > 10, and these tumors would not be downstaged on the basis of ODXRS. In the same respect, although T1-2N0, GR1-2 tumors that are ER þ / PR þ are better candidates to have an ODXRS < 11, these tumors are already pPSG IA, and therefore ODXRS cannot downstage these cases. Similar findings on pathologic parameters predicting LR and HR categories have been published. 17, 18 In our analysis of Ki-67 and ODX risk categories, we found that approximately 20% of vLR cases were high Ki-67, including all 4 cases that changed stage according to ODXRS. Although Ki-67 can assist in understanding tumor biology when combined with other pathologic parameters, additional studies using standardized methods of testing and interpretation of Ki-67 are needed. Not surprisingly, Ki-67 is recognized as AJCC level III evidence because 
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e264 -Clinical Breast Cancer February 2019 of a lack of standardized testing and interpretation, as well as a lack of consensus on an optimal cutoff value. 1 As of the November 2017 update, ODX is the only multigene panel included to classify PPS. 1 Therefore, a possible inadvertent effect that the PPS could have on practice is influencing which panel is ordered. Per the expert panel, substantial data from the MIND-ACT trial could support incorporating MammaPrint for assigning pPSG. 19 However, incorporation has not yet occurred.
Going forward, the expert panel anticipates updates to the staging system at shorter intervals to permit continued refinement of staging criteria. 1 In our study, only rare cases had known recurrence, but in more than half of these cases, the patients' BC was downstaged using the PPS. Of note, 6 cases of recurrence that were downstaged from either stage II or III to stage I had high Ki-67. Five of these 6 cases were grade 3 and/or ODXRS HIR/HR, and 4 of these cases occurred in patients who experienced recurrence within 5 years. 1  ILC  2  80  0  25  T2N0  7  IIA  2  Other  3  100  90  25  T2N0  0  IB  3  IDC  3  90  90  20  T2N0  10  IB  4  IDC  3  95  95  20  T2N0  0 
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Although this is a small number of cases, it highlights possible opportunities for further investigation into additional biomarkers that could contribute to improved discrimination among stage group assignment. Given that the new staging system is only relevant in the context of appropriate therapy, one could make the argument that some of these patients with recurrence may have not received optimal therapy. Of the patients with recurrence whose disease was downstaged to stage I using PPS, only one received systemic chemotherapy.
Recently published results from the TAILORx trial showed that patients with an ODXRS of 11 to 25 do equally as well as patients with an ODXRS of < 11, reporting a 9-year distant recurrence-free survival of 94.5% with adjuvant endocrine therapy alone. 20 It remains to be seen if the PPS table will expand the criteria for pPSG IA to incorporate an ODXRS of 11 to 25. Our data could caution against such a move because the majority of our cases of recurrence had an ODXRS of 11 to 25, with the majority treated systemically with hormone therapy alone, and the majority with distant recurrence. In contrast, only one of our cases of recurrence had an RS < 11, but the recurrence was local, not distant.
In summary, our analysis shows that ODXRS rarely affects staging, and our data are therefore in line with the statements issued in the AJCC 8th edition on ordering multigene panels for IMC. In addition, ordering ODX is most beneficial when pathologic parameters result in uncertainty about whether a patient can be spared chemotherapy. These uncertain cases happen to encompass cases with potential for downstaging on the basis of ODXRS. Therefore, as long as physicians and patients are attuned to the role of ODX in PPS, an increase in ODX testing should not occur in response to the new staging system, particularly for practices where ODX has always been the favored multigene panel. Finally, emphasis should be placed on the fact that the new staging system is only relevant in the context of appropriate therapy, and therefore downstaging of tumors using the PPS should not be used as evidence to withhold therapy.
Clinical Practice Points
Tumors that are T2N0 and either GR3 with high ER and high PR or GR1-2 and ER þ /PRÀ are the most likely to change stage if associated with an ODXRS of < 11. This represents a small subset of cases, and although ODX is included to help classify tumors in the PPS, it rarely results in a change of stage. The PPS assumes that patients will be receiving optimal therapy for their disease, and thus is only relevant in this context.
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